Vitamin D3
Vitamin D3 (cholecalciferol) is a fat-soluble secosteroid hormone precursor, synthesized in skin upon UV-B exposure and obtained through diet and supplementation. Converted to 25(OH)D3 (calcidiol) in liver, then to active 1,25(OH)2D3 (calcitriol) in kidneys. Calcitriol regulates calcium/phosphate homeostasis and activates vitamin D receptors (VDR) present in virtually every cell type. Deficiency (25-OH-D <20 ng/mL) is pandemic, affecting >40% of Americans. Beyond bone metabolism, VDR signaling regulates immunity, muscle function, cardiovascular health, and gene expression of hundreds of genes. Large RCTs (VITAL, etc.) have refined the CV/cancer benefit picture: mortality and cancer benefits seen in true deficiency; supplementation in already-replete individuals shows less clear benefit. Safe at standard doses; toxicity only at extreme doses (>10,000 IU/day long-term without monitoring).
Evidence
Moderate evidence
Safety
Unknown safety profile
Clinical Status
Approved
Research Sync
Feb 19, 2026
Dosing
Set height & weight in Settings to see your dose.
Pharmacology
Evidence Score
Scores estimated from study counts. Exact breakdown computed after research sync.
Plain-English Snapshot
Vitamin D3 is currently categorized as a vitamin mineral compound.
Evidence is moderate (75/100): promising signal from 472 indexed studies, but context and population still matter.
Safety scoring is incomplete. Start conservatively and monitor carefully.
Core mechanism
Precursor to calcitriol; binds vitamin D receptor (nuclear receptor) in all cell types; regulates calcium homeostasis, immunity, muscle function, and expression of 200+ genes
Practical Context
Strongest current signals
- Level A: The role of vitamin D and the VDR gene polymorphism in sepsis risk and mortality: a systematic review and meta-analysis.
- Level B: The Effects of Marine Fatty Acid Omega-3 Supplements on Incident Fractures and Bone Mineral Density in Generally Healthy Adults.
- Level B: Impact of vitamin D supplementation in the prognosis of patients with SARS-CoV2 pneumonia admitted to the intensive care unit - a randomized controlled trial.